|
This information has been developed and provided by an independent third-party source. Merck & Co., Inc. does not endorse and is not responsible for the accuracy of the content, or for practices or
standards of non-Merck sources.
ALERT: U.S. Boxed Warning
The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information. For verbatim wording of the boxed warning, consult the product labeling or www.fda.gov.
Pronunciation
(nor TRIP ti leen)
Generic Available (U.S.)
Yes: Excludes solution
Index Terms
Medication Guide
An FDA-approved patient medication guide, which is available with the product information and at http://www.fda.gov/downloads/Drugs/DrugSafety/ucm088671.pdf, must be dispensed with this medication.
U.S. Brand Names
Canadian Brand Names
Pharmacologic Category
Pharmacologic Category Synonyms
Use: Labeled Indications
Treatment of symptoms of depression
Use: Dental
Treatment of myofascial pain, neuralgia, burning mouth syndrome
Use: Unlabeled/Investigational
Chronic pain (including neuropathic pain), myofascial pain, burning mouth sydrome, anxiety disorders, attention-deficit/hyperactivity disorder (ADHD); enuresis; adjunctive therapy for smoking cessation
Pregnancy Considerations
Animal reproduction studies are inconclusive. Nortriptyline and its metabolites cross the human placenta and can be detected in cord blood. According to the manufacturer, the decision to use nortriptyline during pregnancy or in women of childbearing potential should take into account the potential benefits and possible risks. Treatment algorithms have been developed by the ACOG and the APA for the management of depression in women prior to conception and during pregnancy.
Lactation
Enters breast milk/not recommended (AAP rates “of concern”; AAP 2001 update pending)
Breast-Feeding Considerations
Nortriptyline is excreted into breast milk and the M/P ratio ranged from 0.87 to 3.71 in one study. Based on available information, nortriptyline has not been detected in the serum of nursing infants, however low levels of the active metabolite E-10-hydroxynortriptyline have been detected in the serum of newborns following breast-feeding.
Contraindications
Hypersensitivity to nortriptyline and similar chemical class, or any component of the formulation; use of MAO inhibitors within 14 days; use in a patient during the acute recovery phase of MI
Warnings/Precautions
Boxed warnings:
• Suicidal thinking/behavior: See “Major psychiatric warnings” below.
Major psychiatric warnings:
• [U.S. Boxed Warning]: Antidepressants increase the risk of suicidal thinking and behavior in children, adolescents, and young adults (18-24 years of age) with major depressive disorder (MDD) and other psychiatric disorders; consider risk prior to prescribing. Short-term studies did not show an increased risk in patients >24 years of age and showed a decreased risk in patients ≥65 years. Closely monitor patients for clinical worsening, suicidality, or unusual changes in behavior, particularly during the initial 1-2 months of therapy or during periods of dosage adjustments (increases or decreases); the patient's family or caregiver should be instructed to closely observe the patient and communicate condition with healthcare provider. A medication guide concerning the use of antidepressants should be dispensed with each prescription. Nortriptyline is not FDA approved for use in children.
• The possibility of a suicide attempt is inherent in major depression and may persist until remission occurs. Patients treated with antidepressants should be observed for clinical worsening and suicidality, especially during the initial few months of a course of drug therapy, or at times of dose changes, either increases or decreases. Worsening depression and severe abrupt suicidality that are not part of the presenting symptoms may require discontinuation or modification of drug therapy. Use caution in high-risk patients during initiation of therapy.
• Prescriptions should be written for the smallest quantity consistent with good patient care. The patient's family or caregiver should be alerted to monitor patients for the emergence of suicidality and associated behaviors such as anxiety, agitation, panic attacks, insomnia, irritability, hostility, impulsivity, akathisia, hypomania, and mania; patients should be instructed to notify their healthcare provider if any of these symptoms or worsening depression or psychosis occur.
• May worsen psychosis in some patients or precipitate a shift to mania or hypomania in patients with bipolar disorder. Monotherapy in patients with bipolar disorder should be avoided. Patients presenting with depressive symptoms should be screened for bipolar disorder. Nortriptyline is not FDA approved for the treatment of bipolar depression.
Concerns related to adverse effects:
• Anticholinergic effects: May cause anticholinergic effects (constipation, xerostomia, blurred vision, urinary retention); use with caution in patients with decreased gastrointestinal motility, paralytic ileus, urinary retention, BPH, xerostomia, or visual problems. The degree of anticholinergic blockade produced by this agent is moderate relative to other antidepressants.
• Hematologic effects: TCAs may rarely cause bone marrow suppression; monitor for any signs of infection and obtain CBC if symptoms (eg, fever, sore throat) evident.
• Orthostatic hypotension: May cause orthostatic hypotension (risk is low relative to other antidepressants); use with caution in patients at risk of this effect or in those who would not tolerate transient hypotensive episodes (cerebrovascular disease, cardiovascular disease, hypovolemia, or concurrent medication use which may predispose to hypotension/bradycardia).
• Sedation: May cause sedation, which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving). The degree of sedation is low-moderate relative to other antidepressants.
Disease-related concerns:
• Cardiovascular disease: Use with caution in patients with a history of cardiovascular disease (including previous MI, stroke, tachycardia, or conduction abnormalities); the risk of conduction abnormalities with this agent is moderate relative to other antidepressants.
• Diabetes: Use with caution in patients with diabetes mellitus; may alter glucose regulation.
• Hepatic impairment: Use with caution in patients with hepatic impairment.
• Renal impairment: Use with caution in patients with renal impairment.
• Seizure disorder: Use with caution in patients at risk of seizures, including those with a history of seizures, head trauma, brain damage, alcoholism, or concurrent therapy with medications which may lower seizure threshold.
• Thyroid dysfunction: Use with caution in patients with hyperthyroidism or those receiving thyroid supplementation due to concerns of pro-arrhythmogenesis.
Concurrent drug therapy issues:
• Sedatives: Effects may be potentiated when used with other sedative drugs or ethanol.
Special populations:
• Elderly: Use with caution in the elderly.
Other warnings/precautions:
• Discontinuation of therapy: Recommended to discontinue prior to elective surgery requiring general anesthesia. Therapy should not be abruptly discontinued in patients receiving high doses for prolonged periods.
• Electroconvulsive therapy: May increase the risks associated with electroconvulsive therapy; consider discontinuing, when possible, prior to ECT treatment.
Adverse Reactions
Frequency not defined.
Cardiovascular: Arrhythmia, flushing, heart block, hypertension, MI, palpitation, postural hypotension, tachycardia
Central nervous system: Agitation, anxiety, ataxia, confusion, delirium, delusions, disorientation, dizziness, drowsiness, EEG changes, exacerbation of psychosis, extrapyramidal symptoms, fatigue, hallucinations, headache, hypomania, incoordination, insomnia, nightmares, panic, restlessness, seizure
Dermatologic: Alopecia, itching, petechiae, photosensitivity, rash, urticaria
Endocrine & metabolic: Blood sugar increased/decreased, breast enlargement, galactorrhea, gynecomastia, libido increased/decreased, sexual dysfunction, SIADH
Gastrointestinal: Abdominal cramps, anorexia, black tongue, constipation, diarrhea, epigastric distress, nausea, paralytic ileus, stomatitis, taste disturbance, vomiting, weight gain/loss, xerostomia
Genitourinary: Delayed micturition, impotence, nocturia, polyuria, testicular edema, urinary retention
Hematologic: Agranulocytosis (rare), eosinophilia, purpura, thrombocytopenia
Hepatic: Cholestatic jaundice, transaminases increased
Neuromuscular & skeletal: Numbness, paresthesia, peripheral neuropathy, tingling, tremor, weakness
Ocular: Blurred vision, disturbances in accommodation, eye pain, mydriasis
Otic: Tinnitus
Miscellaneous: Allergic reactions (eg, general edema or of the face/tongue), diaphoresis (excessive), withdrawal symptoms
Metabolism/Transport Effects
Substrate of CYP1A2 (minor), 2C19 (minor), 2D6 (major), 3A4 (minor); Inhibits CYP2D6 (weak), 2E1 (weak)
Drug Interactions
Abiraterone Acetate: May increase the serum concentration of CYP2D6 Substrates. Management: Avoid concurrent use of abiraterone with CYP2D6 substrates that have a narrow therapeutic index whenever possible. When concurrent use is not avoidable, monitor patients closely for signs/symptoms of toxicity. Risk D: Consider therapy modification
Acetylcholinesterase Inhibitors (Central): Anticholinergics may diminish the therapeutic effect of Acetylcholinesterase Inhibitors (Central). Acetylcholinesterase Inhibitors (Central) may diminish the therapeutic effect of Anticholinergics. If the anticholinergic action is a side effect of the agent, the result may be beneficial. Risk C: Monitor therapy
Alfuzosin: May enhance the QTc-prolonging effect of QTc-Prolonging Agents. Risk C: Monitor therapy
Alpha-/Beta-Agonists (Direct-Acting): Tricyclic Antidepressants may enhance the vasopressor effect of Alpha-/Beta-Agonists (Direct-Acting). Exceptions: Dipivefrin. Risk D: Consider therapy modification
Alpha1-Agonists: Tricyclic Antidepressants may enhance the vasopressor effect of Alpha1-Agonists. Risk D: Consider therapy modification
Alpha2-Agonists: Tricyclic Antidepressants may diminish the antihypertensive effect of Alpha2-Agonists. Exceptions: Apraclonidine; Brimonidine. Risk D: Consider therapy modification
Altretamine: May enhance the orthostatic hypotensive effect of Tricyclic Antidepressants. Risk C: Monitor therapy
Amphetamines: Tricyclic Antidepressants may enhance the stimulatory effect of Amphetamines. Tricyclic Antidepressants may also potentiate the cardiovascular effects of Amphetamines. Risk C: Monitor therapy
Anticholinergics: May enhance the adverse/toxic effect of other Anticholinergics. Exceptions: Levocabastine (Nasal); Paliperidone. Risk C: Monitor therapy
Artemether: May enhance the QTc-prolonging effect of QTc-Prolonging Agents. Risk X: Avoid combination
Barbiturates: May increase the metabolism of Tricyclic Antidepressants. Risk D: Consider therapy modification
Beta2-Agonists: Tricyclic Antidepressants may enhance the adverse/toxic effect of Beta2-Agonists. Risk C: Monitor therapy
BuPROPion: May decrease the metabolism of Tricyclic Antidepressants. Risk C: Monitor therapy
CarBAMazepine: May increase the metabolism of Tricyclic Antidepressants. Risk C: Monitor therapy
Chloroquine: May enhance the QTc-prolonging effect of QTc-Prolonging Agents. Risk C: Monitor therapy
Cimetidine: May decrease the metabolism of Tricyclic Antidepressants. Risk C: Monitor therapy
Cinacalcet: May increase the serum concentration of Tricyclic Antidepressants. Risk C: Monitor therapy
Ciprofloxacin: May enhance the QTc-prolonging effect of QTc-Prolonging Agents. Risk C: Monitor therapy
Ciprofloxacin (Systemic): May enhance the QTc-prolonging effect of QTc-Prolonging Agents. Risk C: Monitor therapy
Conivaptan: May increase the serum concentration of CYP3A4 Substrates. Management: Upon completion/discontinuation of conivaptan, allow at least 7 days before initiating therapy with drugs that are CYP3A4 substrates. Risk D: Consider therapy modification
CYP2D6 Inhibitors (Moderate): May decrease the metabolism of CYP2D6 Substrates. Risk C: Monitor therapy
CYP2D6 Inhibitors (Strong): May decrease the metabolism of CYP2D6 Substrates. Risk D: Consider therapy modification
Desmopressin: Tricyclic Antidepressants may enhance the adverse/toxic effect of Desmopressin. Risk C: Monitor therapy
Dexmethylphenidate: May enhance the adverse/toxic effect of Tricyclic Antidepressants. Dexmethylphenidate may increase the serum concentration of Tricyclic Antidepressants. Risk C: Monitor therapy
Divalproex: May increase the serum concentration of Tricyclic Antidepressants. Risk C: Monitor therapy
Dronedarone: QTc-Prolonging Agents may enhance the QTc-prolonging effect of Dronedarone. Risk X: Avoid combination
DULoxetine: May decrease the metabolism of Tricyclic Antidepressants. Risk C: Monitor therapy
Gadobutrol: May enhance the QTc-prolonging effect of QTc-Prolonging Agents. Risk D: Consider therapy modification
Iobenguane I 123: Tricyclic Antidepressants may diminish the therapeutic effect of Iobenguane I 123. Risk X: Avoid combination
Lithium: May enhance the neurotoxic effect of Tricyclic Antidepressants. Risk C: Monitor therapy
Lumefantrine: May enhance the QTc-prolonging effect of QTc-Prolonging Agents. Risk X: Avoid combination
MAO Inhibitors: May enhance the serotonergic effect of Tricyclic Antidepressants. This may cause serotonin syndrome. Risk X: Avoid combination
MAO Inhibitors: May enhance the orthostatic hypotensive effect of Orthostatic Hypotension Producing Agents. Risk C: Monitor therapy
Methylene Blue: Tricyclic Antidepressants may enhance the serotonergic effect of Methylene Blue. This could result in serotonin syndrome. Risk X: Avoid combination
Methylphenidate: May enhance the adverse/toxic effect of Tricyclic Antidepressants. Methylphenidate may increase the serum concentration of Tricyclic Antidepressants. Risk C: Monitor therapy
Metoclopramide: May enhance the adverse/toxic effect of Tricyclic Antidepressants. Management: Seek alternatives to this combination when possible. Monitor patients receiving metoclopramide with tricyclic antidepressants for signs of extrapyramidal symptoms, neuroleptic malignant syndrome, and serotonin syndrome. Risk D: Consider therapy modification
Nilotinib: May enhance the QTc-prolonging effect of QTc-Prolonging Agents. Risk X: Avoid combination
Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates. Risk C: Monitor therapy
Pimozide: QTc-Prolonging Agents may enhance the QTc-prolonging effect of Pimozide. Risk X: Avoid combination
Pramlintide: May enhance the anticholinergic effect of Anticholinergics. These effects are specific to the GI tract. Risk D: Consider therapy modification
Propoxyphene: May enhance the CNS depressant effect of Tricyclic Antidepressants. Risk C: Monitor therapy
Protease Inhibitors: May increase the serum concentration of Tricyclic Antidepressants. Risk C: Monitor therapy
QTc-Prolonging Agents: May enhance the adverse/toxic effect of other QTc-Prolonging Agents. Their effects can be additive, causing life-threatening ventricular arrhythmias. Risk D: Consider therapy modification
QuiNIDine: Tricyclic Antidepressants may enhance the QTc-prolonging effect of QuiNIDine. QuiNIDine may increase the serum concentration of Tricyclic Antidepressants. Risk D: Consider therapy modification
QuiNINE: QTc-Prolonging Agents may enhance the QTc-prolonging effect of QuiNINE. QuiNINE may enhance the QTc-prolonging effect of QTc-Prolonging Agents. Risk X: Avoid combination
Selective Serotonin Reuptake Inhibitors: May decrease the metabolism of Tricyclic Antidepressants. Risk D: Consider therapy modification
Serotonin Modulators: May enhance the adverse/toxic effect of other Serotonin Modulators. The development of serotonin syndrome may occur. Risk D: Consider therapy modification
Sibutramine: May enhance the serotonergic effect of Serotonin Modulators. This may cause serotonin syndrome. Risk X: Avoid combination
Sodium Phosphates: Tricyclic Antidepressants may enhance the adverse/toxic effect of Sodium Phosphates. Specifically, the risk of seizure and/or loss of consciousness may be increased in patients with significant sodium phosphate induced fluid/electrolyte abnormalities. Risk C: Monitor therapy
St Johns Wort: May increase the metabolism of Tricyclic Antidepressants. The risk of serotonin syndrome may theoretically be increased. Risk D: Consider therapy modification
Sulfonylureas: Cyclic Antidepressants may enhance the hypoglycemic effect of Sulfonylureas. Risk C: Monitor therapy
Terbinafine: May decrease the metabolism of Tricyclic Antidepressants. Risk D: Consider therapy modification
Terbinafine (Systemic): May decrease the metabolism of Tricyclic Antidepressants. Risk D: Consider therapy modification
Tetrabenazine: QTc-Prolonging Agents may enhance the QTc-prolonging effect of Tetrabenazine. Risk X: Avoid combination
Thioridazine: QTc-Prolonging Agents may enhance the QTc-prolonging effect of Thioridazine. Risk X: Avoid combination
Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates. Risk C: Monitor therapy
Toremifene: QTc-Prolonging Agents may enhance the QTc-prolonging effect of Toremifene. The risk for potentially dangerous arrhythmias may be increased. Risk X: Avoid combination
TraMADol: Tricyclic Antidepressants may enhance the neuroexcitatory and/or seizure-potentiating effect of TraMADol. Risk C: Monitor therapy
Valproic Acid: May increase the serum concentration of Tricyclic Antidepressants. Risk C: Monitor therapy
Vandetanib: QTc-Prolonging Agents may enhance the arrhythmogenic effect of Vandetanib. Risk X: Avoid combination
Vitamin K Antagonists (eg, warfarin): Tricyclic Antidepressants may enhance the anticoagulant effect of Vitamin K Antagonists. Risk C: Monitor therapy
Yohimbine: Tricyclic Antidepressants may increase the serum concentration of Yohimbine. Risk C: Monitor therapy
Ziprasidone: QTc-Prolonging Agents may enhance the QTc-prolonging effect of Ziprasidone. The risk of a severe arrhythmia may be increased. Risk X: Avoid combination
Ethanol/Nutrition/Herb Interactions
Ethanol: May increase CNS depression; monitor for increased effects with coadministration. Caution patients about effects.
Herb/Nutraceutical: Avoid valerian, St John's wort, SAMe, kava kava (may increase risk of serotonin syndrome and/or excessive sedation).
Storage
Store at 20°C to 25°C (68°F to 77°F). Protect from light.
Mechanism of Action
Traditionally believed to increase the synaptic concentration of serotonin and/or norepinephrine in the central nervous system by inhibition of their reuptake by the presynaptic neuronal membrane. However, additional receptor effects have been found including desensitization of adenyl cyclase, down regulation of beta-adrenergic receptors, and down regulation of serotonin receptors.
Pharmacodynamics/Kinetics
Onset of action: Therapeutic: 1-3 weeks
Distribution: Vd: 21 L/kg
Protein binding: 93% to 95%
Metabolism: Primarily hepatic; extensive first-pass effect
Half-life elimination: 28-31 hours
Time to peak, serum: 7-8.5 hours
Excretion: Urine (as metabolites and small amounts of unchanged drug); feces (small amounts)
Dosage
Oral:
Nocturnal enuresis: Children (unlabeled use): 10-20 mg/day; titrate to a maximum of 40 mg/day
Depression: Children (unlabeled use): 1-3 mg/kg/day
Depression:
Adults: 25 mg 3-4 times/day up to 150 mg/day; doses may be given once daily
Elderly: Initial: 30-50 mg/day, given as a single daily dose or in divided doses. Note: Nortriptyline is one of the best tolerated TCAs in the elderly)
Myofascial pain, neuralgia, burning mouth syndrome (unlabeled uses): Adults: Initial: 10-25 mg at bedtime; dosage may be increased by 25 mg/day weekly, if tolerated; usual maintenance dose: 75 mg as a single bedtime dose or 2 divided doses
Chronic urticaria, angioedema, nocturnal pruritus (unlabeled use): Adults: Oral: 75 mg/day
Smoking cessation (unlabeled use; Fiore, 2008): Adults: Initial: 25 mg/day; titrate dose to 75-100 mg/day 10-28 days prior to selected “quit” date; continue therapy for ≥12 weeks after “quit” day
Dosing adjustment in hepatic impairment: Lower doses and slower titration dependent on individualization of dosage is recommended
Dental Usual Dosing
Myofascial pain, neuralgia, burning mouth syndrome (unlabeled use): Adults: Initial: 10-25 mg at bedtime; dosage may be increased by 25 mg/day weekly, if tolerated; usual maintenance dose: 75 mg as a single bedtime dose or 2 divided doses
Monitoring Parameters
Blood pressure and pulse rate (ECG, cardiac monitoring) prior to and during initial therapy in older adults; weight; blood levels are useful for therapeutic monitoring; suicide ideation (especially at the beginning of therapy or when doses are increased or decreased)
Reference Range
Plasma levels do not always correlate with clinical effectiveness
Therapeutic: 50-150 ng/mL (SI: 190-570 nmol/L)
Toxic: >500 ng/mL (SI: >1900 nmol/L)
Patient Education
Take once-a-day dose at bedtime. Do not increase dose or frequency; may take 2-3 weeks to achieve desired results. Avoid alcohol. Maintain adequate hydration unless instructed to restrict fluid intake. May cause drowsiness, lightheadedness, impaired coordination, dizziness, blurred vision, nausea, vomiting, loss of appetite, disturbed taste, constipation, urinary retention, postural hypotension, altered sexual drive or ability (reversible), or photosensitivity. Report chest pain, palpitations, or rapid heartbeat; persistent adverse CNS effects (eg, suicide ideation, nervousness, restlessness, insomnia, anxiety, excitation, headache, agitation, impaired coordination, changes in cognition); muscle cramping, weakness, tremors, or rigidity; blurred vision or eye pain; breast enlargement or swelling; yellowing of skin or eyes; or worsening of condition.
Geriatric Considerations
Since nortriptyline is the least likely of the tricyclic antidepressants (TCAs) to cause orthostatic hypotension and one of the least anticholinergic and sedating TCAs, it is a preferred agent when a TCA is indicated. Data from a clinical trial comparing fluoxetine to tricyclics suggests that fluoxetine is significantly less effective than nortriptyline in hospitalized elderly patients with unipolar affective disorder, especially those with melancholia and concurrent cardiovascular disease. Paroxetine has been shown to be an equally effective antidepressant compared to nortriptyline in patients with ischemic heart disease. However, nortriptyline was associated a significantly higher rate of adverse cardiac events (sustained increase in heart rate, sinus tachycardia, and asymptomatic increase in ventricular ectopy) compared to placebo.
Additional Information
The maximum antidepressant effect of nortriptyline may not be seen for ≥2 weeks after initiation of therapy.
Dental Health: Effects on Dental Treatment
Key adverse event(s) related to dental treatment: Xerostomia (normal salivary flow resumes upon discontinuation), black tongue, and unpleasant taste. Long-term treatment with TCAs, such as nortriptyline, increases the risk of caries by reducing salivation and salivary buffer capacity.
Dental Health: Vasoconstrictor/Local Anesthetic Precautions
Nortriptyline is one of the drugs confirmed to prolong the QT interval and is accepted as having a risk of causing torsade de pointes. In terms of epinephrine, it is not known what effect vasoconstrictors in the local anesthetic regimen will have in patients with a known history of congenital prolonged QT interval or in patients taking any medication that prolongs the QT interval. Until more information is obtained, it is suggested that the clinician consult with the physician prior to the use of a vasoconstrictor in suspected patients, and that the vasoconstrictor (epinephrine, mepivacaine and levonordefrin [Carbocaine® 2% with Neo-Cobefrin®]) be used with caution. See Dental Health Professional Considerations.
Dental Comment
Nortriptyline is known to prolong the QT interval. The QT interval is measured as the time and distance between the Q point of the QRS complex and the end of the T wave in the ECG tracing. After adjustment for heart rate, the QT interval is defined as prolonged if it is more than 450 msec in men and 460 msec in women. A long QT syndrome was first described in the 1950s and 60s as a congenital syndrome involving QT interval prolongation and syncope and sudden death. Some of the congenital long QT syndromes were characterized by a peculiar electrocardiographic appearance of the QRS complex involving a premature atria beat followed by a pause, then a subsequent sinus beat showing marked QT prolongation and deformity. This type of cardiac arrhythmia was originally termed “torsade de pointes” (translated from the French as “twisting of the points”). Nortriptyline is considered as having a risk of causing torsade de pointes. Since it is not known what effect vasoconstrictors in the local anesthetic regimen will have in patients with a known history of congenital prolonged QT interval or in patients taking any medication that prolongs the QT interval, a medical consult is suggested.
Mental Health: Comment
Tricyclic antidepressants may be classified as tertiary (amitriptyline, doxepin, clomipramine, imipramine, trimipramine) or secondary amines (nortriptyline, desipramine, protriptyline). The tertiary amines are not recommended to treat depression in the elderly. If a TCA is used in the elderly, it should be a secondary amine. The tertiary amines are commonly used in low dosages for various conditions associated with pain. Toxicity is generally dose dependent. Relatively small overdoses (1-week supply) can be potentially fatal.
Plasma concentrations correlate with clinical response. A curvilinear relationship exists.
Nursing: Physical Assessment/Monitoring
Assess for suicidal tendencies before beginning therapy. Assess therapeutic effectiveness (mental status, mood, affect). Monitor for suicide ideation at beginning of therapy and periodically throughout. Taper dosage slowly when discontinuing. Caution patients with diabetes to monitor glucose levels closely; may increase or decrease serum glucose levels.
Dosage Forms
Excipient information presented when available (limited, particularly for generics); consult specific product labeling.
Capsule, oral: 10 mg, 25 mg, 50 mg, 75 mg
Pamelor®: 10 mg, 25 mg
Pamelor®: 50 mg [contains sodium bisulfite (may have trace amounts)]
Pamelor®: 75 mg
Solution, oral: 10 mg/5 mL (473 mL, 480 mL)
Pamelor®: 10 mg/5 mL (480 mL) [contains benzoic acid, ethanol 4%]
Pricing: U.S. (www.drugstore.com)
Capsules (Nortriptyline HCl)
10 mg (90): $21.99
25 mg (30): $12.99
50 mg (30): $17.99
75 mg (30): $18.99
Capsules (Pamelor)
10 mg (30): $695.99
25 mg (30): $695.99
50 mg (30): $695.99
75 mg (30): $541.01
Solution (Nortriptyline HCl)
10 mg/5 mL (473): $52.98
References
American Academy of Pediatrics Committee on Drugs, "Transfer of Drugs and Other Chemicals Into Human Milk," Pediatrics, 2001, 108(3):776-89.
Boakes AJ, Laurence DR, Teoh PC, et al, “Interactions Between Sympathomimetic Amines and Antidepressant Agents in Man,” Br Med J, 1973, 1(5849):311-5.
Boehnert MT and Lovejoy FH Jr, “Value of the QRS Duration Versus the Serum Drug Level in Predicting Seizures and Ventricular Arrhythmias After an Acute Overdose of Tricyclic Antidepressants,” N Engl J Med, 1985, 313(8):474-9.
Buchanan J and Zakrzewska J, “Burning Mouth Syndrome,” Clin Evid (online), March 14, 2008. Available at http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2907957/pdf/2008-1301.pdf
Dawling S, Crome P, and Braithwaite R, “Pharmacokinetics of Single Oral Doses of Nortriptyline in Depressed Elderly Hospital Patients and Young Healthy Volunteers,” Clin Pharmacokinet, 1980, 5(4):394-401.
Frommer DA, Kulig KW, Marx JA, et al, “Tricyclic Antidepressant Overdose,” JAMA, 1987, 257(4):521-6.
Geller B, Cooper TB, Chestnut EC, et al, “Child and Adolescent Nortriptyline Single Dose Kinetics Predict Steady State Plasma Levels and Suggested Dose: Preliminary Data,” J Clin Psychopharmacol, 1985, 5(3):154-8.
Heikkinen T, Ekblad U, and Laine K, “Transplacental Transfer of Amitriptyline and Nortriptyline in Isolated Perfused Human Placenta,” Psychopharmacology (Berl), 2001, 153(4):450-4.
Jastak JT and Yagiela JA, “Vasoconstrictors and Local Anesthesia: A Review and Rationale for Use,” J Am Dent Assoc, 1983, 107(4):623-30.
Larochelle P, Hamet P, and Enjalbert M, “Responses to Tyramine and Norepinephrine After Imipramine and Trazodone,” Clin Pharmacol Ther, 1979, 26(1):24-30.
Levy HB, Harper CR, and Weinberg WA, “A Practical Approach to Children Failing in School,” Pediatr Clin North Am, 1992, 39(4):895-928
Lipper B and Gaynor BD, “Value of Serum Tricyclic Antidepressant Levels With Massive Nortriptyline Overdose and Persistent Hypotension,” Am J Emerg Med, 1995, 13(1):107.
Loughhead AM, Stowe ZN, Newport DJ, et al, “Placental Passage of Tricyclic Antidepressants,” Biol Psychiatry, 2006, 59(3):287-90.
Matheson I and Skjaeraasen J, “Milk Concentrations of Flupenthixol, Nortriptyline and Zuclopenthixol and Between-Breast Differences in Two Patients,” Eur J Clin Pharmacol, 1988, 35(2):217-20.
Mitchell JR, Cavanaugh JH, Arias L, et al, “Guanethidine and Related Agents. III Antagonism by Drugs Which Inhibit the Norepinephrine Pump in Man,” J Clin Invest, 1970, 49(8):1596-604.
Mokhlesi B, Leikin JB, Murray P, et al, “Adult Toxicology in Critical Care: Part II: Specific Poisonings,” Chest, 2003, 123(3):897-922.
Pass SE and Simpson RW, “Discontinuation and Reinstitution of Medications During the Perioperative Period,” Am J Health Syst Pharm, 2004, 61(9):899-912.
Mínguez Serra MP, Salort Llorca C, Silvestre Donat FJ, "Pharmacological Treatment of Burning Mouth Syndrome: A Review and Update," Med Oral Patol Oral Cir Bucal, 2007, 12(4):E299-304.
Prince JB, Wilens TE, Biederman J, et al, “A Controlled Study of Nortriptyline in Children and Adolescents With Attention Deficit Hyperactivity Disorder,” J Child Adolesc Psychopharmacol, 2000, 10(3):193-204.
Prochazka AV, Kick S, Steinbrunn C, et al, “A Randomized Trial of Nortriptyline Combined With Transdermal Nicotine for Smoking Cessation,” Arch Intern Med, 2004, 164(20):2229-33.
Roose SP, Glassman AH, Attia E, et al, “Comparative Efficacy of Selective Serotonin Reuptake Inhibitors and Tricyclics in the Treatment of Melancholia,” Am J Psychiatry, 1994, 151(12):1735-9.
Roose SP, Laghrissi-Thode F, Kennedy JS, et al, “Comparison of Paroxetine and Nortriptyline in Depressed Patients With Ischemic Heart Disease,” JAMA, 1998, 279(4):287-91.
Rundegren J, van Dijken J, Mörnstad H, et al, “Oral Conditions in Patients Receiving Long-Term Treatment With Cyclic Antidepressant Drugs,” Swed Dent J, 1985, 9(2):55-64.
Schneider LS, Cooper TB, Staples FR, et al, “Prediction of Individual Dosage of Nortriptyline in Depressed Elderly Outpatients,” J Clin Psychopharmacol, 1987, 7(5):311-4.
Sunderrajan S, Brooks CS, and Sunderrajan EV, “Nortriptyline-Induced Severe Hyperventilation,” Arch Intern Med, 1985, 145(4):746-7.
Svedmyr N, “The Influence of a Tricyclic Antidepressive Agent (Protriptyline) on Some of the Circulatory Effects of Noradrenaline and Adrenalin in Man,” Life Sci, 1968, 7(1):77-84.
GF and Young MJ, “Criteria for Admitting Patients With Tricyclic Antidepressant Overdose,” J emerge Med, 1988, 6(2):121-4.
turbot J, Norman TR, Burrows GD, et al, “Pharmacokinetics of Nortriptyline in Elderly Volunteers,” commune , 1980, 4(3):225-31.
Wisner KL and Perl JM, “Serum Nortriptyline Levels in Nursing Mothers and Their Infants,” Am J Psychiatry, 1991, 148(9):1234-6.
Yonkers KA, wiser KL, Stewart DE, et al, “The Management of Depression During Pregnancy: A Report From the American Psychiatric Association and the American College of Obstetricians and Gynecologists,” upstate canicola, 2009, 114(3):703-13.
International Brand Names
Lexi-Comp.com
Last full review/revision May 2011
Content last modified May 2011
| 
